Back to Results
First PageMeta Content
GnRH agonists / Leuprorelin / Pharmacology / Precocious puberty / Histrelin / Clinical trial / Puberty / Gonadotropin-releasing hormone / Degarelix / Medicine / Biology / Health


6.7 LEUPRORELIN 30 mg injection: modified release [1 x 30 mg syringe] (&) inert substance diluent [1 x 2 ml syringe], 1 pack; Lucrin Depot Paediatric®; AbbVie Pty Ltd.
Add to Reading List

Document Date: 2015-03-16 01:05:15

Open Document

File Size: 239,65 KB

Share Result on Facebook

City

Trial / /

Company

AbbVie Pty Ltd / n/N (%) LP / GE / Paediatric Medicines Advisory Group / Abbott Endocrine Inc / /

Continent

Australia / /

Country

Australia / /

Currency

USD / /

Event

FDA Phase / /

Facility

Consumer Comments facility / Depot Paediatric VE Category / /

IndustryTerm

treatment of locally advanced or metastatic prostate cancer / similar products / telephone authority / off-label products / treatment for children with progressive disease / clinical management algorithm / /

MedicalCondition

respiratory tract infections / metastatic prostate cancer / disease / headache / progressive disease / central precocious puberty / precocious puberty / /

Organization

Endocrine Society of Australia / /

Position

General / Minister / Program General / nurse / /

Product

Leuprolide Acetate / testosterone / leuprorelin / CP07-167 / /

Technology

ESA / clinical management algorithm / submission Trial ID Protocol / /

SocialTag